153 related articles for article (PubMed ID: 29127379)
1. RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations.
Fischer MM; Yeung VP; Cattaruzza F; Hussein R; Yen WC; Murriel C; Evans JW; O'Young G; Brunner AL; Wang M; Cain J; Cancilla B; Kapoun A; Hoey T
Sci Rep; 2017 Nov; 7(1):15270. PubMed ID: 29127379
[TBL] [Abstract][Full Text] [Related]
2. RSPO3 expands intestinal stem cell and niche compartments and drives tumorigenesis.
Hilkens J; Timmer NC; Boer M; Ikink GJ; Schewe M; Sacchetti A; Koppens MAJ; Song JY; Bakker ERM
Gut; 2017 Jun; 66(6):1095-1105. PubMed ID: 27511199
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.
Chartier C; Raval J; Axelrod F; Bond C; Cain J; Dee-Hoskins C; Ma S; Fischer MM; Shah J; Wei J; Ji M; Lam A; Stroud M; Yen WC; Yeung P; Cancilla B; O'Young G; Wang M; Kapoun AM; Lewicki J; Hoey T; Gurney A
Cancer Res; 2016 Feb; 76(3):713-23. PubMed ID: 26719531
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive characterization of RSPO fusions in colorectal traditional serrated adenomas.
Sekine S; Ogawa R; Hashimoto T; Motohiro K; Yoshida H; Taniguchi H; Saito Y; Yasuhiro O; Ochiai A; Hiraoka N
Histopathology; 2017 Oct; 71(4):601-609. PubMed ID: 28543708
[TBL] [Abstract][Full Text] [Related]
5. R-spondin-3 is an oncogenic driver of poorly differentiated invasive breast cancer.
Ter Steege EJ; Boer M; Timmer NC; Ammerlaan CM; Song JY; Derksen PW; Hilkens J; Bakker ER
J Pathol; 2022 Nov; 258(3):289-299. PubMed ID: 36106661
[TBL] [Abstract][Full Text] [Related]
6. Characterization of RNF43 frameshift mutations that drive Wnt ligand- and R-spondin-dependent colon cancer.
Yamamoto D; Oshima H; Wang D; Takeda H; Kita K; Lei X; Nakayama M; Murakami K; Ohama T; Takemura H; Toyota M; Suzuki H; Inaki N; Oshima M
J Pathol; 2022 May; 257(1):39-52. PubMed ID: 35040131
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer.
Hashimoto T; Takayanagi D; Yonemaru J; Naka T; Nagashima K; Yatabe Y; Shida D; Hamamoto R; Kleeman SO; Leedham SJ; Maughan T; Takashima A; Shiraishi K; Sekine S
Br J Cancer; 2022 Oct; 127(6):1043-1050. PubMed ID: 35715628
[TBL] [Abstract][Full Text] [Related]
8. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
[TBL] [Abstract][Full Text] [Related]
9. R-Spondins 2 and 3 Are Overexpressed in a Subset of Human Colon and Breast Cancers.
Conboy CB; Vélez-Reyes GL; Rathe SK; Abrahante JE; Temiz NA; Burns MB; Harris RS; Starr TK; Largaespada DA
DNA Cell Biol; 2021 Jan; 40(1):70-79. PubMed ID: 33320737
[TBL] [Abstract][Full Text] [Related]
10. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW
Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932
[TBL] [Abstract][Full Text] [Related]
11. WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death.
Fischer MM; Cancilla B; Yeung VP; Cattaruzza F; Chartier C; Murriel CL; Cain J; Tam R; Cheng CY; Evans JW; O'Young G; Song X; Lewicki J; Kapoun AM; Gurney A; Yen WC; Hoey T
Sci Adv; 2017 Jun; 3(6):e1700090. PubMed ID: 28691093
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetics and targeted therapy of WNT-related human diseases (Review).
Katoh M; Katoh M
Int J Mol Med; 2017 Sep; 40(3):587-606. PubMed ID: 28731148
[TBL] [Abstract][Full Text] [Related]
13. Novel Bispecific Domain Antibody to LRP6 Inhibits Wnt and R-spondin Ligand-Induced Wnt Signaling and Tumor Growth.
Jackson H; Granger D; Jones G; Anderson L; Friel S; Rycroft D; Fieles W; Tunstead J; Steward M; Wattam T; Walker A; Griggs J; Al-Hajj M; Shelton C
Mol Cancer Res; 2016 Sep; 14(9):859-68. PubMed ID: 27401612
[TBL] [Abstract][Full Text] [Related]
14. RSPO fusion transcripts in colorectal cancer in Japanese population.
Shinmura K; Kahyo T; Kato H; Igarashi H; Matsuura S; Nakamura S; Kurachi K; Nakamura T; Ogawa H; Funai K; Tanahashi M; Niwa H; Sugimura H
Mol Biol Rep; 2014 Aug; 41(8):5375-84. PubMed ID: 24847761
[TBL] [Abstract][Full Text] [Related]
15. Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions.
Picco G; Petti C; Centonze A; Torchiaro E; Crisafulli G; Novara L; Acquaviva A; Bardelli A; Medico E
EMBO Mol Med; 2017 Mar; 9(3):293-303. PubMed ID: 28100566
[TBL] [Abstract][Full Text] [Related]
16.
Niu J; Guan J; Li R; Li X; Zhai J; Qi J; He Y
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966290
[No Abstract] [Full Text] [Related]
17. RSPO3 promotes the aggressiveness of bladder cancer via Wnt/β-catenin and Hedgehog signaling pathways.
Chen Z; Zhou L; Chen L; Xiong M; Kazobinka G; Pang Z; Hou T
Carcinogenesis; 2019 Apr; 40(2):360-369. PubMed ID: 30329043
[TBL] [Abstract][Full Text] [Related]
18. The role of R-spondin proteins in cancer biology.
Ter Steege EJ; Bakker ERM
Oncogene; 2021 Nov; 40(47):6469-6478. PubMed ID: 34663878
[TBL] [Abstract][Full Text] [Related]
19. Scutellaria barbata D. Don inhibits colorectal cancer growth via suppression of Wnt/β-catenin signaling pathway.
Wei LH; Lin JM; Chu JF; Chen HW; Li QY; Peng J
Chin J Integr Med; 2017 Nov; 23(11):858-863. PubMed ID: 29080197
[TBL] [Abstract][Full Text] [Related]
20. R-spondins can potentiate WNT signaling without LGRs.
Lebensohn AM; Rohatgi R
Elife; 2018 Feb; 7():. PubMed ID: 29405118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
